934240-62-7

Basic information

• Product Name: (2S,5R)-methyl-5-(4-((2-fluorobenzyl)oxy)phenyl)pyrrolidine-2-carboxylate
• Synonyms: (2S,5R)-methyl-5-(4-((2-fluorobenzyl)oxy)phenyl)pyrrolidine-2-carboxylate
• CAS NO: 934240-62-7
• Molecular Weight: 329.371
• Mol File: 934240-62-7.mol
• Article Data: 7

Chemical Properties

• CAS DataBase Reference: (2S,5R)-methyl-5-(4-((2-fluorobenzyl)oxy)phenyl)pyrrolidine-2-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: (2S,5R)-methyl-5-(4-((2-fluorobenzyl)oxy)phenyl)pyrrolidine-2-carboxylate(934240-62-7)
• EPA Substance Registry System: (2S,5R)-methyl-5-(4-((2-fluorobenzyl)oxy)phenyl)pyrrolidine-2-carboxylate(934240-62-7)

Safety Data

• Hazardous Substances Data: 934240-62-7(Hazardous Substances Data)

Upstream product

• 934240-61-6 methyl (S)-5-(4-((2-fluorobenzyl)oxy)phenyl)-3,4-dihydro-2H-pyrrole-2-carboxylate 
• 934240-38-7 (S)-methyl-5-(4-(benzyloxy)phenyl)-3,4-dihydro-2H-pyrrole-2-carboxylate 
• 934584-88-0 (2S,5R)-1-tert-butyl 2-methyl 5-(4-(2-fluorobenzyl)oxy)phenylpyrrolidine-1,2-dicarboxylate 
• 6793-92-6 p-benzyloxyphenylbromide 
• 108963-96-8 (S)-1-tert-butoxycarbonyl-5-methoxycarbonyl-pyrrolidin-2-one 
• 934240-37-6 (S)-methyl 5-(4-(benzyloxy)phenyl)-2-((tert-butoxycarbonyl)amino)-5-oxopentanoate 
• 446-48-0 o-fluorobenzyl bromide 
• 934240-60-5 methyl (S)-2-((tert-butoxycarbonyl)amino)-5-(4-((2-fluorobenzyl)oxy)phenyl)-5-oxopentanoate 
• 106-41-2 4-bromo-phenol 
• 1072951-78-0 (4-((2-fluorobenzyl)oxy)phenyl)boronic acid 
• 183442-88-8 (S)-3-(3-(tert-butoxycarbonyl)-5-oxooxazolidin-4-yl)propanoic acid 
• 934240-59-2 1-[(4-bromophenoxy)methyl]-2-fluorobenzene 

Downstream Products

• 934240-30-9 (2S,5R)-5-(4-((2-fIuorobenzyl)oxy)phenyl)pyrrolidine-2-carboxamide 
• 934585-17-8 2-methyl 1-(phenylmethyl) (2R,5R)-5-(4-{[(2-fluorophenyl)methyl]oxy}phenyl)-2-(hydroxymethyl)-1,2-pyrrolidinedicarboxylate 
• 934585-19-0 (5R)-2-({[(1,1-dimethylethyl)(dimethyl)silyl]oxy}methyl)-5-(4-{[(2-fluorophenyl)methyl]oxy}phenyl)-1-{[(phenylmethyl)oxy]carbonyl}-L-proline 
• 934585-18-9 2-methyl 1-(phenylmethyl) (2R,5R)-2-({[(1,1-dimethylethyl)(dimethyl)silyl]oxy}methyl)-5-(4-{[(2-fluorophenyl)methyl]oxy}phenyl)-1,2-pyrrolidinedicarboxylate 
• 1070868-54-0 (5R)-5-(4-{[(2-fluorophenyl)methyl]oxy}phenyl)-N,N-dimethyl-2-[(methyloxy)methyl]-L-prolinamide 
• 1070868-51-7 (5R)-5-(4-{[(2-fluorophenyl)methyl]oxy}phenyl)-N-methyl-2-[(methyloxy)methyl]-L-prolinamide 
• 1070868-58-4 (5R)-5-(4-{[(2-fluorophenyl)methyl]oxy}phenyl)-2-(hydroxymethyl)-N,N-dimethyl-L-prolinamide 
• 1070868-61-9 (5R)-5-(4-{[(2-fluorophenyl)methyl]oxy}phenyl)-2-(hydroxymethyl)-N-methyl-L-prolinamide 
• 1070868-60-8 (5R)-2-({[(1,1-dimethylethyl)(dimethyl)silyl]oxy}methyl)-5-(4-{[(2-fluorophenyl)methyl]oxy}phenyl)-N-methyl-L-prolinamide 
• 1070868-57-3 (5R)-2-({[(1,1-dimethylethyl)(dimethyl)silyl]oxy}methyl)-5-(4-{[(2-fluorophenyl)methyl]oxy}phenyl)-N,N-dimethyl-L-prolinamide 
• 1070868-42-6 2-methyl 1-(phenylmethyl) (2R,5R)-5-(4-{[(2-fluorophenyl)methyl]oxy}phenyl)-2-[(methyloxy)methyl]-1,2-pyrrolidinedicarboxylate 
• 1070868-53-9 phenylmethyl (2R,5R)-2-[(dimethylamino)carbonyl]-5-(4-{[(2-fluorophenyl)methyl]oxy}phenyl)-2-[(methyloxy)methyl]-1-pyrrolidinecarboxylate 
• 1070868-45-9 (5R)-5-(4-{[(2-fluorophenyl)methyl]oxy}phenyl)-2-[(methyloxy)methyl]-1-{[(phenylmethyl)oxy]carbonyl}-L-proline 
• 1070868-48-2 phenylmethyl (2R,5R)-5-(4-{[(2-fluorophenyl)methyl]oxy}phenyl)-2-[(methylamino)carbonyl]-2-[(methyloxy)methyl]-1-pyrrolidinecarboxylate 

Relevant articles and documents

Synthesis of Vixotrigine, a Use-Dependent Sodium Channel Blocker. Part 1: Development of Bulk Supply Routes to Enable Proof of Concept

Two syntheses of vixotrigine are reported. Route 1, adapted from the medicinal chemistry route, enabled rapid delivery of drug substance for clinical development. Route 2, which was developed to address many of the limitations of Route 1, was used to manu

PROCESS FOR PREPARING ALPHA-CARBOXAMIDE PYRROLIDINE DERIVATIVES

The invention relates to a novel process for preparing a-carboxamide pyrrolidine derivatives, in particular (2S, 5R)-5-(4-((2-fluorobenzyl)oxy)phenyl)pyrrolidine-2-carboxamide, and to novel intermediates for use in said process along with processes for pr

PHARMACEUTICAL COMPOSITIONS COMPRISING 2-METHOXY-5- (5-TRIFLUOROMETHYL-TETRAZOL-I-YL-BENZYL) - (2S-PHENYL-PIPERIDIN-3S-YL-)

The present invention relates to pharmaceutical compositions comprising the NK1 receptor antagonist [2-Methoxy-5-(5-trifuoromethyl-tetrazol-1-yl)-benzyl]-(2S-phenyl- piperidin-3S-yl)-amine, or a pharmaceutically acceptable salt or solvate thereof, and a sodium channel blocker, as a combined preparation for simultaneous or sequential administration and to the use of such compositions in the treatment of certain disorders, including epilepsy, mood disorders and pain.